Effectiveness of combined low-dose radiotherapy and pazopanib for controlling the local manifestations of taxane-resistant recurrent angiosarcoma of the head

Angiosarcomas are soft tissue sarcomas arising in the blood or lymphatic vessels. The scalp and face are the most commonly affected sites. The prognosis of angiosarcoma is poor, with 5-year survival observed in less than 51% of cases.1 Local recurrence after radiotherapy decreases the quality of life. Bleeding from a locally recurrent lesion and pneumohemothorax caused by lung metastasis are the main causes of death in patients with angiosarcoma. Surgical treatment (resection with a wide margin) is usually recommended for local and small lesions, whereas radiotherapy is recommended for large lesions.